NKG2D-CAR-targeted iPSC-derived MSCs efficiently target solid tumors expressing NKG2D ligand

Area of Science:

• Biotechnology
• Cancer Research
• Stem Cell Therapy

Background:

• Mesenchymal stem cells (MSCs) show promise in cancer therapy but suffer from poor tumor homing and heterogeneity.
• Induced pluripotent stem cell (iPSC)-derived MSCs (iMSCs) offer a more homogeneous alternative.
• Enhancing iMSC tumor targeting is crucial for effective cancer treatment.

Purpose of the Study:

• To develop iMSCs with enhanced tumor targeting capabilities.
• To investigate the efficacy of NKG2D-chimeric antigen receptor (CAR) engineering in iMSCs.
• To evaluate the in vitro and in vivo homing and binding of engineered iMSCs to tumor cells.

Main Methods:

• Generated NKG2D-CAR-iPSCs by targeting the B2M locus in iPSCs.
• Differentiated NKG2D-CAR-iPSCs into NKG2D-CAR-iMSCs.
• Assessed in vitro migration and adhesion to tumor cells.
• Performed RNA sequencing to analyze gene expression changes.
• Evaluated tumor homing in an A549 xenograft mouse model.

Main Results:

• NKG2D-CAR engineering significantly enhanced iMSC migration and adhesion to tumor cells expressing NKG2D ligands.
• RNA-seq revealed upregulation of genes associated with cell adhesion and migration in NKG2D-CAR-iMSCs.
• NKG2D-CAR-iMSCs exhibited a 57% improvement in tumor homing compared to unmodified iMSCs in a xenograft model.

Conclusions:

• NKG2D-CAR-iMSCs demonstrate superior targeting specificity for tumor cells expressing NKG2D ligands.
• This engineered cell therapy shows potential as an off-the-shelf living carrier for targeted anti-cancer drug delivery.
• Further investigation into NKG2D-CAR-iMSCs is warranted for advancing cancer therapeutics.